Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | — |
The patient took second dose of Vivotif vaccine on day two instead on day three; Case reference number US-BN-2024-002925 is a spontaneous case initially received from pharmacist via Med Communication (reference number: USBAV24-3373) on 23-Dec-2024 and concerns a adult female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 21-Dec-2024, the patient received first dose of Vivotif vaccine (batch number: unknown), at an unknown dose, route or site of administration for unknown indication. On 22-Dec-2024, one day after the first dose, the patient received second dose of Vivotif vaccine (batch number: unknown), at an unknown dose, route or site of administration. (explicitly coded as 'Inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: An adult female patient of unspecified age received second dose of Vivotif vaccine one day after the first dose, at an unknown dose, route or site of administration which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: An adult female patient of unspecified age received second dose of Vivotif vaccine one day after the first dose, at an unknown dose, route or site of administration which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: NONE